6 Ways Health Companies Can Turn Scientific Evidence Into Sales-Ready Content
How to make health research commercially useful without overstating what the evidence actually proves?
A clinical team approves a carefully worded claim based on a new study. Marketing uses it in an article. Social turns the finding into a shorter, more engaging post. Sales adds it to a presentation and adapts the language to a prospective customer’s priorities. So how did the sales claim become stronger than the clinical evidence supporting it?
Nobody necessarily made a reckless decision. Each person was doing a reasonable job: making technical information easier to understand, more relevant to an audience, or more persuasive in a commercial conversation. The problem emerged as those individual decisions accumulated.
This is a common risk for B2B health companies because scientific evidence rarely stays within the research or clinical team. It moves through articles, campaigns, social media, webinars, sales materials, executive communications and external agencies. At every stage, someone has to decide what to emphasize, what to remove and how to explain why the finding matters.
That creates the conditions for evidence drift: the gradual change in what a piece of research appears to mean as it moves across teams, formats and commercial contexts.
Sometimes evidence drift makes a claim stronger than the research supports. Sometimes it creates inconsistency, with Sales, Marketing and clinical teams describing the same evidence differently. And sometimes companies become so cautious about avoiding either problem that their content remains technically accurate but commercially weak. Buyers are given plenty of evidence without enough help understanding what it means for the decision in front of them.
The answer isn’t to choose between scientific rigor and effective B2B marketing. It’s to build a content process that can preserve the first while creating the second. Here are six ways to do that.
1. Set the claim boundary before Marketing touches the research
Before deciding how to turn research into content, establish what the research actually allows the company to say.
Suppose a study reports an improvement in self-reported stress among a defined group of participants after eight weeks of using a digital mental health intervention. By the time that finding reaches a campaign, it could easily become “proven to reduce employee burnout.”
The new version sounds stronger, but it may also introduce several conclusions the original study never established. Stress and burnout aren’t interchangeable. The participants may not have been employees. An improvement in a self-reported measure doesn’t necessarily establish prevention of an occupational health outcome. And a single study may not justify describing an intervention as “proven.”
B2B health companies don’t need every marketer to conduct a methodological review each time they use a study. They need the people qualified to evaluate the evidence to establish its boundaries before the content production process begins.
For important evidence, that means documenting three things: what the research actually found, what the company can responsibly say on the basis of that finding, and which stronger interpretations the evidence does not support.
Think of this as a claim boundary rather than a finished piece of copy. Marketing should still have considerable freedom to change the framing, language and level of detail. What it shouldn’t have to do is repeatedly decide where the scientific boundary sits.
This is also more efficient than relying on fact-checking at the end of production. If the interpretation is wrong at the beginning, it may already have shaped the headline, campaign angle, sales narrative and supporting assets before anyone reviews the final wording.
For evidence-led health companies, scientific integrity works better as an input to content strategy than as a final compliance check.
2. Translate the relevance, not the result
Once the claim boundary is clear, Marketing has a different job to do. It has to explain why the evidence matters.
This distinction is easy to miss because research findings can sound persuasive on their own. Imagine a study showing that users of a sleep intervention improved their scores on a validated measure of sleep quality.
That’s useful evidence, but an employer is unlikely to buy a workplace health solution because a score on a research instrument increased. The employer is trying to make a business decision and may be thinking about employee needs, adoption, implementation, existing benefits provision and the credibility of the solution.
Marketing therefore needs to connect the scientific finding to that context.
The risk is making the connection too aggressively. Improved sleep quality becomes improved productivity. Improved productivity becomes lower absenteeism. Lower absenteeism becomes a financial return, even though the original research measured none of those outcomes.
A useful discipline is to separate the finding, its relevance and the commercial claim.
The finding describes what the research established. Relevance explains why that information matters in the buyer’s context. The commercial claim describes what the company can credibly say as a result. This distinction gives marketers room to make research useful without making it bigger.
For example, a company doesn’t need to claim that its sleep intervention improves workforce productivity if it has no evidence for that outcome. It can explain why sleep is relevant to employers considering a broader employee wellbeing strategy, while remaining precise about the outcomes its own research actually supports.
The marketer’s job isn’t to make the finding sound more impressive. It’s to make its significance easier for the buyer to understand.
3. Match the proof to the question the buyer is asking
This becomes more important in B2B health because a buying decision rarely depends on one kind of confidence.
A mental health platform selling to an employer may have strong peer-reviewed evidence behind its intervention. That can answer an important scientific question: Does this approach have credible evidence behind it?
But the employer may also be asking: Will our employees use it? Can we implement it successfully? Will it work alongside what we already offer? Is the investment justified?
These are different questions, and a clinical study cannot necessarily answer all of them.
The same applies across stakeholder groups. A clinician may want to understand methodology and clinical boundaries. A benefits consultant may need evidence they can confidently defend when recommending the solution to a client. A strategic partner may care about integration and complementary value. An investor may look at the quality of the evidence alongside adoption, differentiation and the company’s ability to scale.
This means B2B health marketers need to distinguish between several forms of uncertainty. There is scientific uncertainty about whether an intervention works. There is commercial uncertainty about whether it is the right solution for this buyer. There is operational uncertainty about whether it can be implemented effectively. And there may be financial uncertainty about whether the expected value justifies the investment. More scientific information won’t automatically resolve all four.
The practical question is therefore not simply, “What is our strongest evidence?” It is, “What does this buyer still need evidence of before they can move forward?”
This doesn’t mean changing the evidence to suit the audience. It means understanding the job each piece of evidence needs to perform within the buying decision.
4. Stop asking one type of evidence to prove everything
Once you look at evidence through the buyer’s questions, another problem becomes apparent: health companies often have several valuable forms of proof but use them as if they were interchangeable.
Peer-reviewed research, internal outcomes data, product usage statistics, customer case studies, expert opinion and testimonials can all strengthen a B2B buying case. They simply establish different things.
Peer-reviewed research may help establish scientific or clinical credibility. Internal outcomes data can provide evidence about how a specific product performs in practice. Usage data can show whether people engage with it. A case study can demonstrate what implementation looked like inside a real organization. A testimonial can communicate customer experience. Expert commentary can help buyers interpret complex evidence or understand why a finding matters.
Problems arise when one form of evidence is made to do a job it cannot support.
A customer saying that employees loved a wellbeing program is useful social proof, but it doesn’t establish clinical effectiveness. High platform engagement can tell a compelling adoption story, but it doesn’t automatically demonstrate better mental health outcomes. An expert explaining why an intervention is biologically plausible can add valuable context without proving that the intervention works.
The reverse is also true. A randomized controlled trial may provide strong evidence about a specific clinical question while telling an HR leader very little about whether 15,000 employees will adopt the product or whether implementation will create additional work for their benefits team.
This is why the strongest B2B case is rarely one impressive piece of evidence. It is usually the right combination of proof for the decision being made.
For a prospective employer, for example, peer-reviewed research might establish scientific credibility, product data might demonstrate engagement, and a relevant customer case study might reduce implementation uncertainty.
Each piece of evidence becomes more useful when its role is clear.
The goal isn’t to make weaker evidence look stronger. It’s to stop asking scientific evidence to answer commercial questions it was never designed to answer—and to make the actual value of other forms of proof clearer.
5. Change the format without changing what the evidence means
Even when a company establishes clear claims and uses the right evidence for the right questions, another risk appears during execution. Scientific evidence rarely stays in its original format. It has to travel.
Imagine a controlled study finds that participants using a digital mental health intervention reported lower perceived stress scores after eight weeks compared with a control group.
A research summary can describe the methodology, sample, outcome and limitations in detail. A long-form article can explain the result in accessible language, place it within the wider evidence base and discuss what it may mean in practice.
A LinkedIn post has a different job. It might focus on one practical implication of the study and say that new research suggests the intervention may help reduce perceived stress in the population studied. Much of the methodological detail disappears, but the degree of certainty and the outcome being discussed remain recognizable.
A webinar can take the same evidence further by placing it inside a conversation about workplace mental health, bringing in expert interpretation and discussing what employers should consider when assessing interventions. The study becomes one part of a larger argument rather than the argument itself.
Then the finding reaches a sales deck. Space is limited and the buyer wants relevance quickly. “Participants reported lower perceived stress after eight weeks” becomes “Reduces employee stress.”
The wording is cleaner. The claim is also different.
The outcome may have shifted from perceived stress scores to stress. The population may have shifted from the people included in the research to employees generally. “Reported lower” may have become a direct effectiveness claim. Nothing about the slide necessarily looks irresponsible. The problem becomes visible only when you compare it with where the claim started.
This is why good B2B health content requires a distinction between what can change and what needs to remain stable. The depth can change. The terminology can become more accessible. The framing can change according to the buyer. The amount of context can change according to the format.
But information that materially changes the meaning of the evidence—such as the population, outcome, direction of causality or degree of certainty—cannot simply disappear because the format is shorter.
A useful rule is: adapt the communication without upgrading the evidence.
That doesn’t mean every LinkedIn post needs a paragraph of methodological caveats or every sales slide needs a p-value. The useful question is whether removing a piece of context merely makes the communication shorter, or whether it changes what a reasonable reader would think the research established.
The distinction becomes increasingly difficult to manage through individual judgment as more people and channels become involved. At that point, the problem is no longer only copywriting. It becomes a question of communication architecture: whether the company has shared decisions, boundaries and source material that allow different people to adapt important ideas without changing what they mean.
For companies seeing the same problem across positioning, evidence and core claims, it can be useful to examine the communication architecture underneath the content before investing in another round of production.
6. Build a system before evidence starts to drift
Once several teams are using the same research, relying on individual judgment becomes risky and inefficient. Marketing simplifies a claim for a campaign, Sales adapts it for a prospect, and an agency pulls an older version from the website. Each change may seem minor, but over time the company can end up with several interpretations of the same evidence.
The usual response is to add another approval step. That can protect accuracy, but it can also turn clinical or research experts into a bottleneck. A better approach is to make the decisions they would repeatedly have to make available to everyone using the evidence.
Start with a claim record for research that appears regularly in marketing and sales content.
This doesn’t need to be a large database. A simple shared document can capture the source, population studied, outcome measured, strength or type of evidence, important limitations, and the language the company is comfortable using.
For example, instead of saving only the study and expecting every writer to interpret it, the record might state:
Evidence: Participants using the intervention reported lower perceived stress scores after eight weeks compared with the control group.
Supported: “The intervention was associated with lower perceived stress in the study population.”
Needs qualification: “The intervention reduces stress.”
Not supported by this study: “The intervention prevents employee burnout” or “The intervention reduces absenteeism.”
This gives Marketing and Sales a usable starting point without asking them to reconstruct the research every time.
Next, define what can change when the evidence moves between formats and what cannot.
A LinkedIn post can use simpler language than a research report. A sales slide can focus on the finding most relevant to the buyer. A webinar can add expert interpretation. But the population studied, outcome measured, degree of certainty and causal meaning should not quietly change in the process.
It also helps to separate approved claims from approved copy. If teams are given one approved sentence and told to use it everywhere, the result is either repetitive communication or people eventually rewriting it without guidance. Give them the underlying claim and its boundaries instead. They can then adapt the expression to the format while preserving what the evidence means.
Finally, decide which changes actually require expert review.
A writer shouldn’t need a clinical reviewer to approve every shortened sentence. Review should be triggered when the underlying claim changes: for example, when Marketing wants to apply a finding to a new population, connect it to an outcome the study didn’t measure, strengthen causal language, or use new research to replace an existing claim.
This changes the role of research and clinical experts. Instead of repeatedly correcting downstream content, they establish the boundaries that allow other teams to make better decisions independently.
The result is not simply fewer inaccurate claims. Writers spend less time re-researching evidence, Sales knows which claims it can confidently use, agencies work from current information, and reviewers can focus on genuinely new or higher-risk decisions.
That’s what prevents evidence drift at scale: not reviewing every piece of content more carefully, but making the important decisions clear before the content is created.
Making evidence commercially useful without making it scientifically weaker
Scientific evidence and B2B marketing ultimately answer different questions. Research asks what we know, how confidently we know it and under which conditions the finding holds. Marketing has to help a particular buyer understand why any of that matters to the decision they are trying to make.
The difficult work happens between those two questions. If marketers stay too close to the research paper, they can produce content that is accurate but leaves the buyer to interpret its significance alone. If they move too quickly toward commercial outcomes, they can turn relevance into a claim the research never supported.
Strong evidence-led B2B content avoids both. It establishes clear claim boundaries before production begins, connects findings to buyer-relevant questions, uses different forms of proof for different kinds of uncertainty, and preserves the meaning of evidence as it moves across channels and teams.
That is also why scientific credibility cannot be treated only as an editorial standard. Once evidence becomes part of Marketing and Sales, preserving its meaning becomes a content strategy and communication systems problem too.
The objective isn’t to make the evidence sound stronger. It is to make its relevance clearer.
